Daniel D. Brown

Dual HER2/HER3 Targeting with Antibody-Drug Conjugates Reveals a Novel Therapeutic Strategy for HER2-Mutant Lobular Breast Cancer

This study shows HER2 mutations drive HER2/HER3 hyperactivation in ILC, making it sensitive to HER2/HER3-targeting ADCs, and highlights the synergy between T-DXd and P-DXd.

Benchmarking scRNA-seq Copy Number Inference: A Comprehensive Evaluation and Practitioner Guide

This study benchmarks 12 scRNA-seq CNV inference methods across 28 datasets, finding allele-aware tools perform better with high-quality allelic data, while expression-centric tools are reliable with raw data.

Distinct p21 dynamics drive alternative routes to whole-genome duplication through a common CDK4/6-dependent polyploid G0 state

The paper identifies two distinct p21-driven pathways to whole-genome duplication in breast cancer cells, both converging on a CDK4/6-dependent polyploid G0 state, and shows that CDK4/6 inhibitors can block WGD and enhance therapy efficacy.

Role of the NuRD complex and altered proteostasis in cancer cell quiescence

This study identifies NuRD complex downregulation and altered proteostasis in quiescent ovarian cancer cells and shows that targeting these mechanisms can synergistically kill cancer cells.